

FIG. 1 (PRIOR ART)

**MHQVVTLSLILHADSVAGSVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLIFTQONG** 60  
**IWTWNTCTHTYRKDTRYKLLGDLSSRDSLTTENTAVSDSGVYCCRVEHRGWENDMRKTV** 120  
**SLEIVPPKVTTPIVTTVPTVTTVRTSTTVPTTTVPTTMSIPTTTVPTTMTVS** 180  
**TTTSVPTTTSIPTTTSVPVTTTVSTFVPPMPLPRQNHEPVATSPPSSPQAETHPTTLQGA** 240  
**IRREPTSSPLSYTDTGNDIVTESSDGLWNNNNQQLFLEHSLITATKGIYAGVCISVL** 300  
  
**VILLALGVIIAKKIFFRKKEVQQL { RPHKSCICHQRE 334**  
**SVSFSSLIQIKALQNAVEKEVqaedniyiTENSlyATD** 359 (SEQ ID NO:1)

FIG. 2 (PRIOR ART)

Ig-like domain      mucin domain

1 17  $\nabla$  125 311 359  
CCCC CC TSP rich

FIG. 3




FIG. 4




FIG. 5




FIG. 6





FIG. 7






FIG. 8

monoclonal antibodies

8/14

treatment group






FIG. 9

FIG. 10



KIM-1-Ig and control fusion proteins

FIG. 11






FIG. 12A




FIG. 12B

12/14




FIG. 13

13/14




FIG. 14

14/14

FIG. 15A




FIG. 15B

